Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's 3SBio Signs Deal For Isotechnika's Transplant/Immune System Drug Voclosporin After U.S. Delays

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Canada's Isotechnika Pharma has signed a new deal with Chinese drug maker 3SBio on the development and commercialization of Isotechnika's voclosporin, which helps suppress the immune system's rejection of transplanted organs
Advertisement

Related Content

From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step
From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step
Last-Minute Cancellation Of Advisory Panel Meeting Throws Future of Luveniq Into Doubt
3SBio And AMAG Ink Deal To Develop Ferumoxytol In China
3SBio And AMAG Ink Deal To Develop Ferumoxytol In China
Advertisement
UsernamePublicRestriction

Register

SC075748

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel